ã誰ããé¿ããŠéããªãã®ãããããããšããç æ°ã§ãããã®ããããããåŸæ¥ã®åžžèããæ ¹æ¬ãããã€ããã£ããšãã話é¡ããå±ãããŸããã²ãšã€ã¯ãç»åæè¡ã®å€æ§åã§å°ããªåœ±ãŸã§èŠã€ããããã«ãªããããã®éåœã®å€æ§æ§ãããã£ãããšã§ããããã®ããã«èŠããŠããªãããå®ã¯ãã€ãŸã§çµã£ãŠã倧ãããªããªããã®ããããã¯éäžã§æ¶ããŠããŸããã®ãªã©ãå€ããå¿ ããããããïŒæ»ãã§ã¯ãªããªããŸããã
ãããã²ãšã€ã¯ãããã®æ°ããè¬ãç¶ã ãšç»å Žããæãã䜿ãããŠãããããã®è¬ãã®è©äŸ¡ã極端ã«äžãã£ãŠããŸã£ãããšã§ããã©ãããããšããææ°ã®ãšããã³ã¹ãèŠãŠãããŸãããã
䜿çšæ©äŒæžãååŠçæ³å€
ãããã®è¬ã«ã¯ã倧ããåããŠ3ã€ãããŸããæãã䜿ãããŠããã®ããååŠçæ³å€ãã§ããåãæ°ãè±æ¯ãäžç¢ãªã©ã®åŒ·ãå¯äœçšã¯åºãç¥ãããŠãããšããã§ãããã®åŸãç»å Žããã®ããã«ã¢ã³çæ³å€ã§ããããšãã°åç«è ºããã¯ç·æ§ãã«ã¢ã³ãããŸãä¹³ããã¯å¥³æ§ãã«ã¢ã³ããããã®å¢æ®ãããããä¿é²ããŠããŸãããããããã®åããæããç©è³ªãæ²»çè¬ãšããŠäœ¿ãããŠããŸãããããŠææ°ã®è¬ããååæšççæ³å€ãšåŒã°ãããã现èã ãã«äœçšããŠå¢æ®ã転移ãæã蟌ããã®ã§ãã
ãããŠãããçã«ãããããã®ã¯ååŠçæ³å€ã§ãããããšãã°ä»£è¡šçãªè¬ã®ã²ãšã€ã·ã¹ãã©ãã³ã¯ããã现èã®DNAã«å ¥ã蟌ãã§å¢æ®ãæ¢ãããšããåããããŸãããããšèšºæãããå€ãã®äººãïŒæ¬äººã¯ç¥ããªããšãïŒäœ¿ãããŠããã¯ãã§ãããã现èã¯åè£é »åºŠãé«ãããããã®è¬ãå¹ããããã¯ãããšããçå±ãªã®ã§ããã容æã«æ³åã§ããããã«å¥åº·ãªçŽ°èããå·å®³ããŠããŸããŸãã
ãååŠçæ³å€ã®å¯äœçšã®ãªãã§ãææªãªã®ã¯ãçºãããã§ããäžé©åãªæ²»çãåå ã§ããããæ°ãã«çºçããããšãããããäºæ¬¡ããããšåŒã°ããŸãããããæ£ã£ãŠãäžåºŠã¯å埩ããã¯ãã®äººãããã®åŸã次ã ã«å¥ã®ãããçºçããããšããããŸããããã®åå ã®ã²ãšã€ãååŠçæ³å€ã ã£ããšããããã§ãã
ã詳现ã¯æèãããæ€èšºã®å€§çœªãïŒæ°æœ®éžæžïŒã«è²ããŸãããååŠçæ³å€ã§ãæãããªå»¶åœå¹æãã蚌æããããã®ã¯ãã²ãšã€ããããŸããã§ãããå°é家ãååŠçæ³å€ã䜿ãæ ¹æ ãšããåŠè¡æç®ã¯ããããããã®ã§ãããããããªç 究ãå€ããä»®ã«ããŒã¿ãæ£ããã£ããšããŠãã寿åœãããããæ°ã«æ延ã³ãã ãããšãããã®ã°ããã§ãããããã«ãããããããããã®å°éå»ã¯æããå€ã«åºå·ããŠããããšããæŽå²ããããŸãã
ãä¹³ããã察象ã«ãååŠçæ³å€ãã©ãããã䜿ãããŠããã®ããç±³åœã§èª¿æ»ãè¡ãããŸãããããã«ãããšã30幎åã¯ããæ£è ã®95ããŒã»ã³ãã«äœ¿ãããŠããŸãããã10幎åã«çŽ35ããŒã»ã³ãã3幎åã«ã¯19ããŒã»ã³ãã«ãŸã§æžã£ãŠããããšãããããŸããã
ãç±³åœã®ãã倧åŠææã¯ãã20幎ã»ã©åã¯ãååŠçæ³å€ã2çš®é¡äœ¿ããã3çš®é¡ã«ããããšããè°è«ãå°éå»ãã¡ã®äž»ãªé¢å¿äºã ã£ãã4çš®é¡ãå¿ èŠã ãšããç 究ã話é¡ã«ãªã£ãŠããæ代ã§ãããããæ¯ã¹ããšéäžã®æãããããšèªã£ãŠããŸãã
ååæšççæ³å€ã«æªç¥ã®äœçš
ãçŸåšãããæ²»çã«æºããå»åž«ãé¢å¿ãå¯ããŠããã®ããåè¿°ãããååæšççæ³å€ãã§ããããšãã°ãä¹³ãããèããæ²»çã«äœ¿ãããŠããã®ãããŒã»ããã³ãšããè¬ã§ãã䜿çšã¯ãããé¢é£èçœããªããã®ãéºäŒçã«æã£ãŠãã人ã«éãããã®ã§ãããä¹³ããæ£è ã§å»¶åœå¹æããããšããã泚ç®ãããŠããŸãããã®æ°ããè¬ããåŸæ¥ã®ååŠçæ³å€ãšäžç·ã«äœ¿ã£ãå Žåãšãåç¬ã§äœ¿ã£ãå Žåãæ¯ã¹ããšããèšåºè©Šéšãè¡ãããŸããããšããã䞡矀ã®å»¶åœçã«ã¯ãéãããã£ããèªããããŸããã§ããã
ãã€ãŸããååŠçæ³å€ã¯ãããªãè¬ã ã£ãã®ã§ããå¯äœçšã«èŠãããããŠãã人ã«ãšã£ãŠã¯ãä»ããèšãããŠãçŽåŸã§ããªã話ãããããŸããã
ãããã«ãæ°è¬ã§ãããããšãã£ãŠåªããŠãããšãéããŸãããä»ãããå°éå»ã®æ³šç®ãéããŠããææ°ã®ååæšççæ³å€ã§ãããå€æ°ã®èšåºè©Šéšãè¡ãããŠããã«ãããããããèªå¯ãããã«è³ã£ãã®ã¯ãããã3ããŒã»ã³ããããããŸãããã€ãŸããã»ãšãã©ã®è¬ãéçºã«å€±æããŠããã®ã§ãã
ãç±³åœã®ç 究è ã¯ããã现èãéºäŒåæäœã§åŸ¹åºçã«èª¿ã¹ã倱æã®çç±ã調ã¹ãŠããŸããååæšççæ³å€ã¯ãããã现èã®åè£ãä¿é²ãããç©è³ªãããã³ãã€ã³ãã§æã蟌ããšããè¬ã§ãããããã£ãŠããã®ç©è³ªãããåãé€ããŠããŸãã°ãè¬ã¯ç¡æå³ã«ãªãã¯ãã§ããããšãããããã®ãããªåŠçãæœãã现èã«è¬ãäžãããšãããåŠçåãšå€ãããªãå¹æãèªããããã®ã§ããã€ãŸãããããã®è¬ã«ã¯éçºè ã®æå³ãšç°ãªãæªç¥ã®äœçšããããããããããªããŸãŸäœ¿ãããŠããããšã«ãªããŸãã
ãæè¿ãããã«ã€ããŠãããã²ãšã€æ°çºèŠããããŸãããäŒç äžã®ãã现èããããããšã«ãªã£ãŠæŽãåºãããšããããšããäºå®ã§ãããããã¯ãªãåçºããã®ãããšããé·å¹Žã®çåã«å¯ŸããçããšãèããããŠããŸããå°ã£ãããšã«äŒç 现èã«ã¯ããããŸã§ã®è¬ãå¹ããŸããã
ãããã®å®æ ããè¬ã®æ矩ãããŸããŸãããããªããªã£ãŠããŸãããããªãããããæããå€æ²»çãåããç¶æ³ã«ãªã£ããããŸãèªåã§ããå匷ããå¿ èŠããããŸãããã®äžã§ãè€æ°ã®å°éå»ããæèŠãèããã©ãããã決ããã»ããããããã§ãã
ïŒæïŒå²¡ç°æ£åœŠïŒæ°æœå€§åŠåèªææïŒ
åèæç®
ã1ã  Goodwin PJ, Extended aromatase inhibitors in hormone-receptor-positive cancer. N Engl J Med, Jul 29, 2021.
ã2ã  Berger S, This breast cancer gene is less well known, but nearly as dangerous. New York Times, Aug 17, 2021.
ã3ã  Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med, Sep 11, 2019.
ã4ã  Zimmer C, Why arenât cancer drugs better? The targets might be wrong. New York Times, Sep 17, 2019.
ã5ã  Targeted therapy to treat cancer, what is targeted therapy? National Cancer Institute, Mar 11, 2020.
ã6ã  Kolata G, Cancer without chemotherapy: âa totally different world.â New York Times, Sep 28, 2021.